ITCI - Intra-Cellular Therapies, Inc.
131.87
-0.050 -0.038%
Share volume: 16,062,974
Last Updated: 04-01-2025
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$131.92
-0.05
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-07-2024 | 08-07-2024 | 10-30-2024 | 02-21-2025 | |
| Total revenue | 144.866 M | 161.388 M | 175.375 M | 199.223 M | |
| Cost of revenue | 9.900 M | 11.354 M | 15.304 M | 20.405 M | |
| Gross profit | 134.966 M | 150.034 M | 160.071 M | 178.818 M | |
| 11.16% | 6.69% | 11.71% | |||
| Operating expenses | 155.918 M | 177.757 M | 198.920 M | 208.015 M | |
| Selling general and admin | 113.085 M | 121.574 M | 132.101 M | 137.729 M | |
| Research and development | 42.833 M | 56.183 M | 66.819 M | 70.286 M | |
| Total expenses | 155.918 M | 177.757 M | 198.920 M | 208.015 M | |
| 14.01% | 11.91% | 4.57% | |||
| Operating income | -20.952 M | -27.723 M | -38.849 M | -29.197 M | |
| Ebit | -20.952 M | -27.723 M | -38.849 M | -29.197 M | |
| Pretax income | -14.888 M | -16.163 M | -25.950 M | -17.202 M | |
| 8.56% | 60.55% | -33.71% | |||
| Income tax | 359.000 K | 57.000 K | 374.000 K | -317.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -15.247 M | -16.220 M | -26.324 M | -16.885 M | |
| -6.38% | -62.29% | 35.86% |